Veronique D'Hondt (Véronique D'Hondt, Véronique D'hondt)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Metastatic Colorectal Cancer

Ejection Fraction

Placebo Controlled

Top Venues

Breast cancer research and treatment

International journal of molecular sciences

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Leticia Aptecar, Carole Puech, Evelyne Lopez-Crapez, Marion Peter, Peter J Coopman, Veronique D'Hondt, Gilles Freiss
PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells. International journal of molecular sciences 24 (20) (2023)
Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, Lisa Belin, Katharina Leitner, David Cibula, Hannelore G Denys, Ora Rosengarten, Manuel J Rodrigues, Nikolaus de Gregorio, Jerónimo Martínez-Garcia, Edgar Petru, Roman Kocian, Ignace Vergote, Patricia Pautier, Barbara Schmalfeldt, Lydia Gaba, Stephan Polterauer, Marie-Ange Mouret Reynier, Jalid Sehouli, Cristina Churruca, Frédéric Selle, Florence Joly Lobbedez, Veronique D'Hondt, Émilie Bultot-Boissier, Coriolan Lebreton, Jean-Pierre Lotz, Rémy Largillier, Pierre Etienne Heudel, Florian Heitz, null null
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Julie A Vendrell, Iulian O Ban, Isabelle Solassol, Patricia Audran, Simon Cabello-Aguilar, Delphine Topart, Clothilde Lindet-Bourgeois, Pierre-Emmanuel Colombo, Eric Legouffe, Veronique D'Hondt, Michel Fabbro, Jean-Marc Rey
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. International journal of molecular sciences 24 (18) (2023)
Angelique Bobrie, Marta Jarlier, Aurore Moussion, William Jacot, Veronique D'Hondt
Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30 (4) (2022)
Leticia Aptecar, Frederic Fiteni, Marta Jarlier, Stephanie Delaine, Violaine Guillerme, William Jacot, Veronique D'Hondt
Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients. Breast cancer research and treatment 186 (3) (2021)